The change in those photos is a real biological effect with an unreal context. Melanotan II mimics a hormone that tells pigment cells to make more melanin, so skin darkens. It has no approval as a drug or a cosmetic anywhere, no verified supply, and the pigment cells it stimulates are the same cells melanoma comes from.
The vocabulary, in plain terms
| Term | What it means without the jargon |
|---|---|
| Melanocyte | The cell in the lower layer of the epidermis that manufactures pigment and hands it to surrounding skin cells |
| Melanin | The pigment itself. More of it means darker skin and a small amount of natural sun protection |
| Alpha-MSH | A hormone the body makes that tells melanocytes to switch pigment production up |
| Melanocortin 1 receptor | The docking point on the melanocyte that alpha-MSH binds to. Variation in this receptor is a large part of why skin and hair color differ between people |
| Melanotan II | A synthetic, chemically stabilized imitation of alpha-MSH that binds several melanocortin receptors rather than just the one in skin |
| Afamelanotide | A different synthetic analogue that does have an approved product, an implant prescribed for a rare light sensitivity disorder |
| Nevus | A mole. A cluster of melanocytes, which respond to the same signal the rest of the skin does |
| Dihydroxyacetone | The active ingredient in self-tanning lotions. It colors dead surface cells and never reaches a melanocyte |
| Research chemical | A labeling convention asserting a product is not for human use, which keeps the seller outside drug regulation |
What is happening between the two frames
A tan from sunlight is a damage response. Ultraviolet light injures skin cells, those cells signal, and melanocytes answer by producing more pigment. A tan from an alpha-MSH analogue skips the injury and goes straight to the signal. That is why the effect can appear without sun exposure and why people describe it as a shortcut.
The shortcut has a structural flaw. The signal is not selective. It reaches every melanocyte reachable, including the ones packed together inside a mole, which is why the same mechanism that produces an even tan also darkens existing moles and can prompt new pigmented lesions to appear. A published review of eruptive melanocytic nevi that gathered 179 patients from the literature found that immunosuppressive agents, chemotherapy or melanotan accounted for 41 percent of the identified precipitating causes.
Why that matters more than it sounds
Skin cancer screening works by pattern recognition. A dermatologist compares a lesion against its neighbors and against how it looked before, and acts on lesions that break the pattern. A drug that darkens everything and adds new spots interferes with both halves of that comparison at once. The approved product in this receptor class states the issue directly in its prescribing information: it can cause generalized increased pigmentation and darkening of pre-existing moles and freckles as a pharmacologic effect, and a twice yearly full body skin examination is recommended so that pigmented lesions stay monitored. That recommendation is attached to a product administered by a trained clinician for a diagnosed condition. Nothing equivalent accompanies a vial bought online.
The approved analogue is not the same product
Afamelanotide is worth understanding because sellers borrow its credibility. It is approved under a new drug application as an implant, is inserted subcutaneously by a health professional who has completed manufacturer training, and is indicated to increase pain free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. That is a rare inherited disorder in which sunlight causes severe pain. The label carries hypersensitivity warnings including anaphylaxis, and its trial safety table records nausea in 19 percent of treated patients and melanocytic nevus in 4 percent against 2 percent on vehicle. Approval for a photosensitivity condition is not approval for a cosmetic tan, and the two products are not interchangeable in any sense.
What “unapproved” actually means for a buyer
For an approved injectable, four things are settled before anyone receives it. Identity, meaning the vial holds the molecule on the label. Purity, meaning impurities are named and limited. Potency, meaning the stated amount matches the real amount across shelf life. Sterility, meaning the preparation carries no organisms or endotoxin. Melanotan II has none of that infrastructure. It was nominated for the list of bulk substances usable in compounding, the nomination was withdrawn, and FDA published its safety concerns in the same table, citing published case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome and priapism.
There is also a practical asymmetry between buying routes that has nothing to do with the molecule. A prescription route produces a named pharmacy, a named prescriber and a lot number, and it produces the possibility of being told no. Reference material published by supervised providers reflects that, and the page FormBlends maintains on this subject states that the compound sits outside what the provider works with, pointing readers to supervised care for metabolic health instead. A vendor page has no mechanism for declining a customer, which is the whole point of the model.
The regulated way to get the same appearance
Dihydroxyacetone works by chemistry rather than biology. It reacts with amino acids in the dead outer layer of skin to form brown pigments, an ordinary non-enzymatic browning reaction, and the color sheds as those cells do over several days. Because it never touches a melanocyte, it cannot darken a mole or add a new one. FDA lists it as a color additive for imparting color to the human body restricted to external application, which excludes the lips, other mucous membrane surfaces and the area of the eye. Products without sunscreen ingredients must carry a warning stating that they do not protect against sunburn, and that warning is worth taking at face value.
Regulated care for these categories is not hard to locate either. A set of licensed telehealth companies competes in the open, with Henry Meds, Ro and Hims and Hers moving metabolic and hormone patients through prescribers, and HealthRX describing its peptide therapy options only where an approved product and a real supply chain exist. Melanotan II for tanning sits on none of those service lines, which is the working difference between a supervised clinician and an anonymous vial.
Frequently asked questions
If the tan is real, why call the photos misleading?
Because a photograph documents appearance and nothing else. It cannot show what was in the vial, whether sun or a sunbed contributed, or what a dermatologist would see under dermoscopy. The visible result is the least uncertain part of the story and the least important part of the decision.
Does melanotan II protect against sunburn?
Induced pigment offers only a small amount of protection at best, and no controlled study has measured it for this compound in people. Several documented cases involve users combining injections with sunbed sessions, so in practice the exposure often goes up rather than down.
Is the nasal spray version a different product?
It is the same unapproved substance in a different presentation, with the same unknowns about content and purity. A published case report describes mucosal melanoma in a young woman who had used a melanotan II nasal spray for tanning, so changing the route does not remove the pigment cell concern.
What should someone do about a mole that darkened?
Have it examined, and say that melanocyte stimulation happened. Dermatologists read changing lesions differently when they know a pigment signal was applied, and a lesion that grew or altered in shape needs assessment regardless of whether the overall tan has since faded.
